Cell-Cycle Non-Specific (CCNS) — oncology-focused definition
Cell-cycle non-specific (CCNS) drugs are anticancer agents that can kill cancer cells at any phase of the cell cycle, including both dividing and resting (G₀) cells.
Key Points:
- Not dependent on cell division to exert cytotoxicity.
- Often used in high tumor burden or slow-growing tumors where cells may be in different phases of the cell cycle.
- Can affect both cancerous and normal rapidly dividing cells, leading to toxicity.
Examples of CCNS Drugs
| Drug Class | Examples | Mechanism / Notes |
|---|---|---|
| Alkylating agents | Cyclophosphamide, Ifosfamide, Cisplatin | Crosslink DNA → apoptosis; active in all phases |
| Anthracyclines | Doxorubicin, Epirubicin | Intercalates DNA, inhibits topoisomerase II, generates free radicals |
| Platinum compounds | Carboplatin, Oxaliplatin | DNA crosslinking, apoptosis |
| Nitrosoureas | Carmustine, Lomustine | DNA alkylation, lipid-soluble → crosses BBB |
Clinical relevance (for oncology pharmacists):
- Can be combined with cell-cycle specific drugs (like antimetabolites or taxanes) for synergistic effect.
- Toxicity monitoring is essential due to effects on bone marrow, GI tract, and hair follicles.
- Useful in tumors with low proliferative fraction, e.g., slow-growing lymphomas or solid tumors.
Key takeaway:
CCNS drugs kill cancer cells regardless of their position in the cell cycle, making them versatile in cancer therapy but requiring careful monitoring for myelosuppression and other toxicities.
Synonyms
CCNS